PKU GOLIKE Debuts at SSIEM 2018 Conference: Science Driven Innovation behind the Medical Food for PKU Management of APR Applied Pharma Research
APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, has successfully concluded its participation at the recent SSIEM (Society for the Study of Inborn Errors of Metabolism) Conference held in Athens. The company has taken advantage of this international event, gathering around 3.000 physicians involved in inherited metabolic diseases, to showcase PKU GOLIKE®, the innovative Phenylalanine (Phe)-free medical food formula for Phenylketonuria (PKU), powered by the patented Physiomimic Technology TM .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180913005450/en/
PKU GOLIKE. Feel the change: Join the evolution in nutritional management (Photo: APR Applied Pharma Research)
PKU GOLIKE® is a brand new generation of medical food formulas for oral use consisting of a prolonged released amino acid (AA) mixture without Phe (with or without vitamins and minerals), providing a physiological absorption of the AAs as well as a remarkable masking of odor and taste, while minimizing the unpleasant after-taste typical of free AAs.
The large attendance at APR’s sponsored satellite symposium “Physiological Absorption of Amino Acids: Rationale and Expected Benefits”, involving renown international experts in PKU, represented the ideal occasion to divulge details regarding PKU GOLIKE® and the Physiomimic TechnologyTM . During the symposium, it was highlighted how this drug delivery technology can effectively prolong the release of the amino acids (AAs) and support their physiological absorption.
In particular, a study in human subjects demonstrated that significant reductions of the AAs absorption peaks were obtained with PKU GOLIKE®, when compared with the same AAs mixture without the application of the technology. The reduction of the absorption peaks, associated with a similar bioavailability of the AAs, allows reducing AA fluctuations in favor of an improved efficiency in the use of AAs.
The same cross over human study also demonstrated a reduction of Phe fluctuations over time, deriving from body metabolism of the study subjects receiving Phe-free PKU GOLIKE® in fasting conditions, with respect to the fluctuations measured when free AAs were consumed.
Overall, the scientific data of PKU GOLIKE® presented at this meeting open new avenues for research in nutrition, aimed at providing data useful to patients to improve the efficiency of the dietary management of their disorder.
Throughout the lifetime of the event, APR’s staff has been very busy at the company booth with welcoming a high number of physicians from all over the world eager to gather more information about PKU GOLIKE®. Visitors’ questions regarded, in particular, the patented Physiomimic™ Technology - how it works and the benefits of its application to the innovative amino acids mixture. They also had the chance to get to know PKU GOLIKE® range, made of three different AA mixes suitable for PKU patients of different ages, as well as to experience the special coating micro granules containing the exclusive formulation of AAs.
Physicians and dieticians who tasted the product were extremely surprised to find out how the Physiomimic Technology TM is actually able to remarkably mask the unpleasant taste and odor of AAs, thus being confirmed on the extent of this significant advantage for PKU patients’ compliance to dietary regimen.
The venue offered also the opportunity to arrange several meetings with potential business partners, who could appraise the extent of the company innovation appeal and be informed about APR’s projects in the inherited metabolic diseases.
“We are very pleased by the positive reactions of the medical community to our innovation. As father of a PKU child, I was quite conscious of the clinical and nutritional gaps in PKU management still unresolved. We decided to apply our deep know-how in drug delivery technologies and systems to offer to PKU patients’ a new treatment option, the benefits of which are confirmed by the preclinical and clinical data generated so far.” said Paolo Galfetti, CEO of APR Applied Pharma Research. “Now, we look forward to take to fruition of PKU patients and care givers this innovative product line and to further support our innovation by generating additional scientific data in the coming future”.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/
APR Applied Pharma Research s.a.:
Paolo Galfetti, +41 91 6957020
Chief Executive Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30 | Pressemelding
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,
Quanergy Selected as Exclusive LiDAR Partner for VRCO21.9.2018 05:00 | Pressemelding
Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, and VRCO, designer and manufacturer of the luxury high-end e-VTOL (electric Vertical Take-Off and Landing) craft, the NeoXcraft XP2, today announced that VRCO will exclusively use Quanergy’s S3 solid state LiDAR sensors in the testing and market release versions of the aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006036/en/ VRCO NeoXcraft XP2 with Quanergy S3 LiDAR Sensor (Graphic: Business Wire) The NeoXcraft XP2, which VRCO and the University of Derby unveiled in late 2017 and intend to launch in 2020, is a two-passenger e-VTOL high-speed land, air, and water capable craft. The craft can scan and memorize take-off locations and store the data for use on the next approach to the same location. Quanergy’s innovative S3 solid state LiDAR sensor will be used for downward and forward
Overseas Roadshow for the IAPH Guangzhou 2019 World Ports Conference Was Held in London21.9.2018 03:08 | Pressemelding
Overseas roadshow for the IAPH Guangzhou 2019 World Ports Conference was successfully held in Armourer's Hall, London, UK on September 20th. Ms. Yuan Yue, Deputy Director General of Guangzhou Port Authority, met with over 100 senior representatives from British ports, ship-owners, commodity traders, shipping & service companies, shipping public policy research institutes, and other representatives from the port and shipping industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006031/en/ Speech made by Lord Jeffrey Evans, Chairman of Maritime London (Photo: Business Wire) In her keynote speech, Ms. Yuan Yue said, “Guangzhou is the gateway city of South China and is known as the “Millennium Business Capital” and a popular destination for business and investment. At present, Guangzhou has attracted investors from over 130 countries. Nearly 300 of the world's top 500 companies have businesses and investment in Guangzho
AbuDhabi Dubai STOB Series 22 Investment Enters into Favorable Tender Offer Agreement with MINDOL HOLDINGS21.9.2018 01:00 | Pressemelding
AbuDhabi Dubai STOB Series 22 Investment Limited Partnership, hereafter AbuDhabi22, and MINDOL HOLDINGS LIMITED, hereafter MINDOL, listed on the Hong Kong-based Coinsuper exchange (https://www.coinsuper.com) have reached an agreement where AbuDhabi22 will acquire the minimum 33.3 percent holding for the MINDOL cryptocurrency (MIN, https://mindol.net) to be issued by MINDOL, via a tender offer (TOB). Implementation of the TOB will serve to strengthen the strategic partnership with MINDOL. Both companies expect that the AbuDhabi22 bid will greatly exceed any bids made via ordinary exchange channels. With a bid offering at a stable price, the TOB method was chosen for its strategic worth. The MINDOL business vision for 2019 sets a target for its cryptocurrency, from among the more than 2,000 types of cryptocurrencies currently available, to have a top-30 market capitalization. As a business that focuses on "the fusion of subculture and blockchain," they will develop an online game that ta
Afton Chemical’s S$380 Million Phase II Expansion of Its Jurong Island Plant is Now Complete20.9.2018 21:07 | Pressemelding
Afton Chemical Corporation, a global leader in the lubricant and fuel additive market, today announced the completion of the Phase II expansion of its Chemical Additive Manufacturing Facility in Jurong Island, Singapore. This milestone was marked by a special visit from Singapore’s Minister for Trade & Industry Mr. Chan Chun Sing, who also made a speech and toured the facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005903/en/ Afton Chemical Corporation – Singapore Chemical Additive Manufacturing Facility Phase II Expansion (Photo: Business Wire) As a wholly owned subsidiary of NewMarket Corporation (NYSE: NEU), Afton has been a leading player in the lubricant and fuel additive marketplace for over 90 years. The company was founded on a Passion for Solutions® and has maintained a focus on customizing commercial and industrial solutions that meet customer needs. Afton begun its Singapore manufacturing operations
IFF Announces Pricing of €1,100,000,000 Senior Notes Offering20.9.2018 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of €300,000,000 aggregate principal amount of its 0.500% senior notes due 2021 and €800,000,000 aggregate principal amount of its 1.800% senior notes due 2026. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 25, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required to redeem all of the notes on the special mandatory redemption date at a redem